LeMaitre Vascular (NASDAQ:LMAT) Earns Buy (B-) Rating from Weiss Ratings

Key Points

• LeMaitre Vascular's stock has been given a "buy (B-)" rating by Weiss Ratings, reflecting positive analyst sentiment.
• The company reported $0.60 earnings per share for the last quarter, beating estimates and showing a 15% increase in revenue compared to the previous year.
• Recent insider selling included a director offloading 2,500 shares, decreasing their ownership by over 46%, which may indicate potential concerns among insiders.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report)'s stock had its "buy (b-)" rating reiterated by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald raised their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Barrington Research restated an "outperform" rating and set a $95.00 price target on shares of LeMaitre Vascular in a research note on Tuesday, September 23rd. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular currently has an average rating of "Moderate Buy" and a consensus price target of $97.60.

LeMaitre Vascular Trading Up 1.4%

Shares of LeMaitre Vascular stock opened at $88.04 on Wednesday. The firm's 50-day moving average price is $91.97 and its two-hundred day moving average price is $86.33. LeMaitre Vascular has a 12-month low of $71.42 and a 12-month high of $109.58. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of 42.74, a PEG ratio of 2.24 and a beta of 0.77.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. During the same period last year, the company posted $0.52 EPS. The firm's quarterly revenue was up 15.0% compared to the same quarter last year. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction on Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the sale, the director owned 2,916 shares in the company, valued at $274,104. The trade was a 46.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David B. Roberts sold 10,815 shares of the firm's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the transaction, the director directly owned 17,976 shares of the company's stock, valued at $1,660,802.64. This represents a 37.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,815 shares of company stock worth $11,280,206 over the last ninety days. Company insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On LeMaitre Vascular

Large investors have recently modified their holdings of the stock. Parkside Financial Bank & Trust raised its position in LeMaitre Vascular by 1,913.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 287 shares during the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular during the 1st quarter valued at about $26,000. NBC Securities Inc. bought a new stake in shares of LeMaitre Vascular during the 1st quarter valued at about $36,000. Geneos Wealth Management Inc. grew its stake in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after acquiring an additional 398 shares during the period. Finally, EverSource Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter valued at approximately $47,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.